2816 completed, 740 unknown, 297 terminated, 209 recruiting. 882 Phase 2, 724 Phase 3, 685 Phase 4, 591 Phase 1, 579 Not applicable.
Follow Hepatitis: new trials by email Literature Review of Hepatitis trials Research Report on Hepatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans Integrated care - Opioid Use Disorder, HIV | Not applicable | Not yet recruiting | VA Office of Research and Development | 60 | 2028-04-03 | 2026-04-24 |
| Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D Hepalatide 2.1mg, Placebo of Hepalatide - Hepatitis D, Chronic | Phase 3 | Not yet recruiting | Shanghai HEP Pharmaceutical Co., Ltd. | 150 | 2027-06-01 | 2026-10-28 |
| Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health. Gardasil 9 vaccine, Hepatitis B Virus Vaccine(HBV), Cognitive Behavioral Therapy - Hepatitis B, Human Papilloma Virus | Phase 4 | Not yet recruiting | Eunice Dube | 2140 | 2027-01-30 | 2026-07-30 |
| Combating Related Epidemics in HCV Cepheid GeneXpert HCV Test, Abbott Determine HIV - 1/2 Ag/Ab, Abbott Determine HbsAg 2 - HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV) | Phase 4 | Not yet recruiting | Duke University | 1280 | 2027-01-20 | 2026-10-15 |
| A Phase 1 Clinical Trial of Adjuvanted Protein-based HCV Vaccine Candidates (HCV Vaccine Trial) AVIHepC1, Normal Saline - Hepatitis C | Phase 1 | Not yet recruiting | University of Alberta | 27 | 2027-01-15 | 2026-09-25 |
| A Trial of Inebilizumab in Participants With Autoimmune Hepatitis Inebilizumab, Placebo, Standard of Care - Autoimmune Hepatitis, AIH | Phase 3 | Recruiting | Amgen | 180 | 2026-12-18 | 2026-11-03 |
| B-Ensure: Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants Bepirovirsen - Hepatitis B | Phase 4 | Not yet recruiting | GlaxoSmithKline | 303 | 2026-12-03 | 2026-11-02 |
| Targeting ANKRD11 Reverses HBV-Specific CD8+ T Cell Dysfunction and Tolerance Chronic Hepatitis B | Not yet recruiting | Beijing Municipal Administration of Hospitals | 40 | 2026-12-01 | 2026-08-28 | |
| AI-Powered Hepatitis C Single-Encounter Test-and-Treat Epclusa (sofosbuvir and velpatasvir) - HEPATITIS C (HCV) | Phase 4 | Not yet recruiting | Patrick Grace | 35 | 2026-12-01 | 2026-08-28 |
| A Prospective Study to Evaluate the Efficacy and Safety of Entecavir ODT Conversion in Stable Liver Transplant Patients Entecavell ODT - Hepatitis B Virus, Liver Transplant | Phase 2 | Not yet recruiting | Jongman Kim | 82 | 2026-12-01 | 2026-10-28 |
| A Study to Compare Blood Levels of Bepirovirsen and Safety Using Different Methods of Injecting in Healthy Adult Participants Bepirovirsen - Hepatitis B | Phase 1 | Not yet recruiting | GlaxoSmithKline | 98 | 2026-11-03 | 2026-10-29 |
| ED Patient's Perceptions and Acceptability Toward a Novel POC HCV Viral Load Testing Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid) - Hepatitis C | Not applicable | Not yet recruiting | Johns Hopkins University | 200 | 2026-11-01 | 2025-11-10 |
| Clinical Study to Evaluate the Performance of the INSTI® HCV Antibody Test for CLIA-Waived Use INSTI HCV Antibody Test - HCV Infection | Not applicable | Not yet recruiting | bioLytical Laboratories | 388 | 2026-11-01 | 2026-10-29 |
| Study to Evaluate the Performance of the INSTI® HCV Antibody Test for Point-of-Care Use in Individuals at Risk for HCV Infection or Presenting With Signs or Symptoms of HCV Infection INSTI HCV Antibody Test - HCV Infection | Not applicable | Not yet recruiting | bioLytical Laboratories | 1660 | 2026-11-01 | 2026-10-29 |
| HIV/HBV/HCV Triple Screening in Primary Care electronic medical record alert linked to orders - HIV, HBV (Hepatitis B Virus) | Not applicable | Recruiting | University of Texas Southwestern Medical Center | 50 | 2026-11-01 | 2026-10-29 |
| A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB) AHB-137, Placebo, TVAX-008 - Chronic Hepatitis B | Phase 1 / Phase 2 | Not yet recruiting | Ausper Biopharma Co., Ltd. | 105 | 2026-10-31 | 2026-10-19 |
| A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB) AHB-137, TVAX-008, Placebo - Chronic Hepatitis B | Phase 1 / Phase 2 | Not yet recruiting | Grand Theravac Life Sciences (Hangzhou) Co., Ltd. | 105 | 2026-10-31 | 2026-10-27 |
| Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B ACT500 Tablets, ACT500 Placebo Tablets - Metabolic Dysfunction-associated Steatotic Liver Disease, Chronic Hepatitis b | Phase 1 | Not yet recruiting | Xiamen Amoytop Biotech Co., Ltd. | 24 | 2026-10-30 | 2026-09-14 |
| A Study of HT-101 and HT-102 in Chronic Hepatitis B (CHB) HT-101 + HT-102, HT-101 placebo + HT-102 placebo - Chronic Hepatitis B Virus Infection | Phase 2 | Not yet recruiting | Suzhou HepaThera Biotech Co., Ltd. | 120 | 2026-10-30 | 2026-11-05 |
| A Clinical Study of AHB-121 in Healthy Participants and Chronic Hepatitis B (CHB) Participants AHB-121, Placebo - Chronic Hepatitis B Virus | Phase 1 | Not yet recruiting | Ausper Biopharma Co., Ltd. | 110 | 2026-10-28 | 2026-10-21 |
Showing 20 of 4437. Sign in to see all of them.
Hepatitis C (1721) · Hepatitis B (1005) · Hepatitis C, Chronic (907) · Hepatitis B, Chronic (865) · HIV Infections (193) · Fibrosis (185) · Liver Cirrhosis (157) · Carcinoma, Hepatocellular (136) · Liver Diseases (127) · Acquired Immunodeficiency Syndrome (120) · Hepatitis, Alcoholic (108) · Tetanus (107) · Diphtheria (101) · Haemophilus Infections (82)
Digestive System Diseases (4416) · Liver Diseases (4310) · Infections (4084) · Virus Diseases (4053) · Hepatitis, Viral, Human (4020) · Blood-Borne Infections (3930) · Communicable Diseases (3917) · RNA Virus Infections (2650) · Flaviviridae Infections (2304) · Pathological Conditions, Signs and Symptoms (2205) · Pathologic Processes (2184) · Disease Attributes (1943) · Chronic Disease (1873) · Hepatitis, Chronic (1842)
Ribavirin (667) · peginterferon alfa-2a (423) · entecavir (201) · Tenofovir (188) · Sofosbuvir (180) · peginterferon alfa-2b (180) · daclatasvir (100) · sofosbuvir-velpatasvir drug combination (79) · Hepatitis B Vaccines (78) · Simeprevir (72) · ledipasvir, sofosbuvir drug combination (71) · telaprevir (71) · Lamivudine (68) · Ritonavir (67) · tenofovir alafenamide (67)
GlaxoSmithKline (192) · Merck Sharp & Dohme LLC (186) · Gilead Sciences (171) · Hoffmann-La Roche (140) · Bristol-Myers Squibb (126) · AbbVie (91) · National Taiwan University Hospital (61) · National Institute of Allergy and Infectious Diseases (NIAID) (60) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (50) · Third Affiliated Hospital, Sun Yat-Sen University (47) · ANRS, Emerging Infectious Diseases (41) · Kirby Institute (37) · Sanofi Pasteur, a Sanofi Company (34) · Beijing Ditan Hospital (32) · Assiut University (31)
United States (1231) · China (606) · France (391) · Canada (316) · Germany (315) · South Korea (262) · United Kingdom (261) · Spain (252) · Taiwan (247) · Australia (234) · Italy (204) · New Zealand (191) · Belgium (189) · Puerto Rico (171) · Poland (131)
Chen-Hua Liu, MD (18) · Liang Peng, Doctor (13)
PMID 30739368, PMID 30977945, PMID 30012435, PMID 30923816, PMID 28193518, PMID 29461687, PMID 31568620, PMID 28427875, PMID 30529905, PMID 29377566, PMID 29404492, PMID 19052126, PMID 23607594, PMID 25445400, PMID 28404091, PMID 28404092, PMID 30868245, PMID 32710245, PMID 41586499, PMID 24209977, PMID 24915612, PMID 25040192, PMID 25583164, PMID 26575258, PMID 26683763, PMID 27847279, PMID 29405329, PMID 30664876, PMID 33460002, PMID 35174470, PMID 35599306, PMID 37096802, PMID 37771546, PMID 15470215, PMID 19187608, PMID 21182232, PMID 22436845, PMID 22821361, PMID 23046671, PMID 23518903, PMID 23607593, PMID 24329937, PMID 25348661, PMID 25987775, PMID 26743093, PMID 26947564, PMID 27553375, PMID 27658343, PMID 29756595, PMID 35941076
2014 (45), 2015 (43), 2016 (27), 2009 (26), 2019 (13), 2008 (12), 2017 (11), 2004 (10), 2005 (7), 2023 (7), 2025 (7), U01DK082864 (7), 2018 (5), U01DK082843 (5), U01DK082871 (5)